Table 5.
Factors associated with mortality in patients with nirmatrelvir/ritonavir administration.
| Univariable analysis |
Multivariable analysis |
|||||||
|---|---|---|---|---|---|---|---|---|
| p value | HR | 95% CI |
p value | HR | 95% CI |
|||
| Lower limit | Upper limit | Lower limit | Upper limit | |||||
| Sex | ||||||||
| Female | – | – | – | – | ||||
| Male | 0.234 | 2.644 | 0.533 | 13.116 | ||||
| Age | 0.332 | 1.029 | 0.972 | 1.089 | ||||
| Comorbidities at COVID-19 onset | ||||||||
| Chronic cardiopathy | 0.063 | 7.479 | 0.900 | 62.169 | 0.092 | 6.761 | 0.731 | 62.532 |
| Chronic pulmonary disease | 0.619 | 0.044 | 0.000 | . | ||||
| Diabetes mellitus | 0.056 | 5.001 | 0.957 | 26.126 | 0.167 | 4.229 | 0.547 | 32.698 |
| Liver disease | 0.720 | 0.046 | 0.000 | . | ||||
| Obesity | . | . | . | . | ||||
| Renal failure | 0.799 | 0.048 | 0.000 | . | ||||
| Smoking history | 0.626 | 0.044 | 0.000 | . | ||||
| No comorbidity | 0.122 | 0.191 | 0.023 | 1.555 | ||||
| Neutrophils at COVID-19 onset | ||||||||
| <501 | – | – | – | – | ||||
| 501–999 | 0.642 | 0.512 | 0.030 | 8.614 | ||||
| >999 | 0.172 | 0.210 | 0.022 | 1.970 | ||||
| Lymphocytes at COVID-19 onset | ||||||||
| <201 | – | – | – | – | ||||
| 201–499 | 0.640 | 0.563 | 0.051 | 6.249 | ||||
| >499 | 0.149 | 0.266 | 0.044 | 1.607 | ||||
| Status malignancy at COVID-19 onset | ||||||||
| Controlled disease | – | – | – | – | – | – | – | – |
| Stable disease | 0.980 | 0.000 | 0.000 | . | 0.950 | 0.000 | 0.000 | . |
| Active disease | 0.064 | 4.721 | 0.915 | 24.354 | 0.311 | 2.462 | 0.431 | 14.060 |
| Unknown | 0.993 | 0.000 | 0.000 | . | 0.995 | 0.000 | 0.000 | . |
| Baseline malignancy at COVID-19 onset | ||||||||
| Leukaemia | – | – | – | – | ||||
| Lymphoma | 0.837 | 0.863 | 0.213 | 3.492 | ||||
| PH negative myeloproliferative diseases | 0.989 | 0.000 | 0.000 | . | ||||
| Plasma cell disorders | 0.971 | 0.000 | 0.000 | . | ||||
| Symptoms at COVID-19 onset | ||||||||
| Pulmonary | – | – | – | – | ||||
| Pulmonary + extrapulmonary | 0.966 | 0.968 | 0.212 | 4.419 | ||||
| Extrapulmonary | 0.305 | 0.299 | 0.030 | 3.001 | ||||
| Screening | 0.988 | 0.000 | 0.000 | . | ||||
| SARS-CoV-2 vaccination status at COVID-19 onset | ||||||||
| Not vaccinated | – | – | – | – | ||||
| One dose | 0.940 | . | 0.000 | . | ||||
| Two doses | 0.920 | . | 0.000 | . | ||||
| Three doses | 0.924 | . | 0.000 | . | ||||
| Four doses | 0.980 | 1735.991 | 0.000 | . | ||||
| ICU admission | 0.106 | 3.614 | 0.760 | 17.178 | ||||
| Nirmatrelvir/ritonavir line | ||||||||
| Other line | – | – | – | – | ||||
| First line | 0.997 | 1.003 | 0.188 | 5.349 | ||||
| Days from COVID-19 onset to nirmatrelvir/ritonavir treatment | 0.771 | 1.003 | 0.980 | 1.027 | ||||
| Stay during COVID-19 episode | ||||||||
| Home | – | – | – | – | ||||
| Hospital | 0.171 | 4.387 | 0.528 | 36.477 | ||||
This table includes patients from European institutions.
CI, confidence interval; COVID-19, coronavirus 2019 disease; HR, hazard ratio; ICU, intensive care unit; PH, Philadelphia; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.